Literature DB >> 24374652

Preoperative radiation for retroperitoneal sarcoma is not associated with increased early postoperative morbidity.

Edmund K Bartlett1, Robert E Roses, Chelsey Meise, Douglas L Fraker, Rachel R Kelz, Giorgos C Karakousis.   

Abstract

BACKGROUND AND OBJECTIVES: Preoperative radiation (PR) in the management of retroperitoneal sarcoma (RPS) is controversial. Concern for increased perioperative morbidity may influence the decision to recommend PR. Here we compare 30-day morbidity and mortality (M + M) after resection of RPS with and without PR.
METHODS: Patients undergoing resection of RPS were identified using ACS NSQIP (2005-2011). Patients with known PR status within 90 days of operation were included. Univariate and multivariate logistic regression analyses were performed to identify factors associated with M + M.
RESULTS: Of 696 patients operated on for RPS, 70 (10%) underwent PR. PR patients were younger (mean 55 vs. 61 years), more frequently had hypoalbuminemia (<3 g/dl; 19% vs. 10%), concomitant kidney (29% vs. 18%), or pancreas resections (11% vs. 5%), longer operations (mean 327 vs. 253 min), and increased transfusion requirements (mean 4.1 vs. 2.1 units, each P < 0.05). Despite these differences, the M + M rate (31% with vs. 30% without PR, P = 0.75) was comparable between the two groups. After adjustment for confounders, no association was identified between PR and M + M.
CONCLUSIONS: In a national cohort of RPS patients, PR is infrequently utilized. Despite the increased prevalence of multiple risk factors, PR patients do not have an increased 30-day postoperative M + M.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  morbidity and mortality; neoadjuvant radiation; retroperitoneal sarcoma

Mesh:

Year:  2013        PMID: 24374652     DOI: 10.1002/jso.23534

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  10 in total

1.  Does neoadjuvant chemotherapy affect morbidity, mortality, reoperations, or readmissions in patients undergoing lumpectomy or mastectomy for breast cancer?

Authors:  Jeffrey Landercasper; Barbara Bennie; Mallory S Bray; Choua A Vang; Jared H Linebarger
Journal:  Gland Surg       Date:  2017-02

Review 2.  Soft tissue sarcoma and radiation therapy advances, impact on toxicity.

Authors:  Nancy El-Bared; Philip Wong; Dian Wang
Journal:  Curr Treat Options Oncol       Date:  2015-05

3.  Long-term Oncologic Outcomes After Neoadjuvant Radiation Therapy for Retroperitoneal Sarcomas.

Authors:  Daniel P Nussbaum; Paul J Speicher; Brian C Gulack; Asvin M Ganapathi; Brian R Englum; David G Kirsch; Douglas S Tyler; Dan G Blazer
Journal:  Ann Surg       Date:  2015-07       Impact factor: 12.969

Review 4.  Surgical management of retroperitoneal and pelvic sarcomas.

Authors:  Marcus C B Tan; Sam S Yoon
Journal:  J Surg Oncol       Date:  2014-12-05       Impact factor: 3.454

Review 5.  The effect of neoadjuvant radiation therapy on perioperative outcomes among patients undergoing resection of retroperitoneal sarcomas.

Authors:  Daniel P Nussbaum; Paul J Speicher; Brian C Gulack; Asvin M Ganapathi; Jeffrey E Keenan; Sandra S Stinnett; David G Kirsch; Douglas S Tyler; Dan G Blazer
Journal:  Surg Oncol       Date:  2014-07-23       Impact factor: 3.279

6.  Does neoadjuvant therapy for esophageal cancer increase postoperative morbidity or mortality?

Authors:  B Mungo; D Molena; M Stem; S C Yang; R J Battafarano; M V Brock; A O Lidor
Journal:  Dis Esophagus       Date:  2014-07-24       Impact factor: 3.429

7.  Alteration of renal Na,K-ATPase in rats following the mediastinal γ-irradiation.

Authors:  Barbora Kaločayová; Ivona Kovačičová; Jana Radošinská; Ľubomíra Tóthová; Lucia Jagmaševič-Mézešová; Marko Fülöp; Ján Slezák; Pavel Babál; Pavol Janega; Norbert Vrbjar
Journal:  Physiol Rep       Date:  2019-02

8.  Favorable control of rapidly progressive retroperitoneal pleomorphic leiomyosarcoma with multimodality therapy: a case report.

Authors:  Kosuke Sagara; Kotoe Takayoshi; Eiji Kusumoto; Keita Uchino; Taisei Matsumura; Hitoshi Kusaba; Seiya Momosaki; Koji Ikejiri; Eishi Baba
Journal:  BMC Res Notes       Date:  2014-06-19

9.  Clinical phase I/II trial to investigate preoperative dose-escalated intensity-modulated radiation therapy (IMRT) and intraoperative radiation therapy (IORT) in patients with retroperitoneal soft tissue sarcoma: interim analysis.

Authors:  Falk Roeder; Alexis Ulrich; Gregor Habl; Matthias Uhl; Ladan Saleh-Ebrahimi; Peter E Huber; Daniela Schulz-Ertner; Anna V Nikoghosyan; Ingo Alldinger; Robert Krempien; Gunhild Mechtersheimer; Frank W Hensley; Juergen Debus; Marc Bischof
Journal:  BMC Cancer       Date:  2014-08-27       Impact factor: 4.430

10.  Using the revised Edmonton symptom assessment scale during neoadjuvant radiotherapy for retroperitoneal sarcoma.

Authors:  Russell F Palm; Heather S L Jim; David Boulware; Peter A S Johnstone; Arash O Naghavi
Journal:  Clin Transl Radiat Oncol       Date:  2020-02-28
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.